SNG-2003

N/A

Report date: 2022/01/05 15:24:33

Base Information

Drug NameSNG-2003

Drug Alias NameSNG-2003

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibody

Mechanisms of ActionAnti-Programmed death-ligand 1Anti-TGF-β

TargetsTransforming growth factor betaProgrammed death-ligand 1

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsEsophageal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesBeijing Shenogen Biomedical Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesBeijing Shenogen Biomedical Co Ltd

Inactive CompaniesN/A

Active IndicationsCarcinoma, Non-Small-Cell LungStomach NeoplasmsEsophageal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A